Next Article in Journal
The Virology of Taterapox Virus In Vitro
Previous Article in Journal
The Pandemic Threat of Emerging H5 and H7 Avian Influenza Viruses
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessArticle
Viruses 2018, 10(9), 462;

Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection

AbbVie, Inc., North Chicago, IL 60064, USA
Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX 78215, USA
Author to whom correspondence should be addressed.
Received: 18 July 2018 / Revised: 21 August 2018 / Accepted: 27 August 2018 / Published: 28 August 2018
(This article belongs to the Section Antivirals & Vaccines)
Full-Text   |   PDF [631 KB, uploaded 28 August 2018]   |  


Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) are potent and pangenotypic hepatitis C virus (HCV) direct-acting antivirals. This report describes the baseline polymorphisms and treatment-emergent substitutions in NS3 or NS5A detected in samples from HCV genotype 1-infected patients receiving 3-day monotherapy of glecaprevir or pibrentasvir, respectively. None of the NS3 polymorphisms detected in the 47 baseline samples collected prior to glecaprevir monotherapy conferred reduced susceptibility to glecaprevir. The NS3 A156T substitution, which conferred resistance to glecaprevir but had low replication efficiency, emerged in one genotype 1a-infected patient among the 35 patients with available post-baseline sequence data. Baseline NS5A polymorphisms were detected in 12 of 40 patients prior to pibrentasvir monotherapy; most polymorphisms were single-position NS5A amino acid substitutions that did not confer resistance to pibrentasvir. Among the 19 patients with available post-baseline NS5A sequence data, 3 had treatment-emergent NS5A substitutions during pibrentasvir monotherapy. All treatment-emergent NS5A substitutions were linked multiple-position, almost exclusively double-position, substitutions that conferred resistance to pibrentasvir. Replicons engineered with these double-position substitutions had low replication efficiency. In conclusion, resistance-conferring substitutions emerged in a small number of genotype 1-infected patients during glecaprevir or pibrentasvir monotherapy; unlike other NS5A inhibitors, pibrentasvir did not select single-position NS5A substitutions during monotherapy. View Full-Text
Keywords: glecaprevir; pibrentasvir; monotherapy; resistance; HCV; ABT-493; ABT-530 glecaprevir; pibrentasvir; monotherapy; resistance; HCV; ABT-493; ABT-530

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Ng, T.I.; Pilot-Matias, T.; Tripathi, R.; Schnell, G.; Krishnan, P.; Reisch, T.; Beyer, J.; Dekhtyar, T.; Irvin, M.; Lu, L.; Asatryan, A.; Campbell, A.; Yao, B.; Lovell, S.; Mensa, F.; Lawitz, E.J.; Kort, J.; Collins, C. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection. Viruses 2018, 10, 462.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top